{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:32Z","timestamp":1792003532533,"version":"4.4.0"},"reference-count":89,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Research, Innovation and Digitization, CCCDI\u2014UEFISCDI","award":["PN-III-P2-2.1-PED-2021-2243"],"award-info":[{"award-number":["PN-III-P2-2.1-PED-2021-2243"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic, immune-mediated, inflammatory disease that has a major impact on patients\u2019 quality of life. Common psoriasis-associated comorbidities include cardiovascular diseases, psoriatic arthritis, inflammatory bowel syndromes, type-2 diabetes, and metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is affecting a substantial portion of the population and is closely linked with psoriasis. The interplay involves low-grade chronic inflammation, insulin resistance, and genetic factors. The review presents the pathophysiological connections between psoriasis and nonalcoholic fatty liver disease, emphasizing the role of cytokines, adipokines, and inflammatory cascades. The \u201chepato-dermal axis\u201d is introduced, highlighting how psoriatic inflammation potentiates hepatic inflammation and vice versa. According to the new guidelines, the preliminary examination for individuals with psoriasis should encompass evaluations of transaminase levels and ultrasound scans as part of the initial assessment for this cohort. Considering the interplay, recent guidelines recommend screening for NAFLD in moderate-to-severe psoriasis cases. Treatment implications arise, particularly with medications impacting liver function. Understanding the intricate relationship between psoriasis and NAFLD provides valuable insights into shared pathogenetic mechanisms. This knowledge has significant clinical implications, guiding screening practices, treatment decisions, and the development of future therapeutic approaches for these chronic conditions.<\/jats:p>","DOI":"10.3390\/ijms25052660","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:50:23Z","timestamp":1708930223000},"page":"2660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet\u2014A Comprehensive Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-8654","authenticated-orcid":false,"given":"Daniel","family":"Costache","sequence":"first","affiliation":[{"name":"Discipline of Dermatology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Dermatology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia","family":"Blejan","sequence":"additional","affiliation":[{"name":"Dermatology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Ioni\u021b\u0103","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Poenaru","sequence":"additional","affiliation":[{"name":"Dermatology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-3236","authenticated-orcid":false,"given":"Maria","family":"Constantin","sequence":"additional","affiliation":[{"name":"Discipline of Dermatology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"2nd Dermatology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Costache","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7965","authenticated-orcid":false,"given":"Constantin","family":"C\u0103runtu","sequence":"additional","affiliation":[{"name":"Discipline of Internal Medicine and Gastroenterology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-8041","authenticated-orcid":false,"given":"Daniel","family":"Balaban","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"},{"name":"Discipline of Physiology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-5550","authenticated-orcid":false,"given":"Raluca","family":"Costache","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Carol Davila Central Emergency Military University Hospital, 010825 Bucharest, Romania"},{"name":"Discipline of Physiology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Academy of Romanian Scientists, 050091 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"ref_1","unstructured":"Callen, J.P., Cowen, E.W., and Hruza, G.J. (2018). Dermatology, Elsevier Limited. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Costache, D.O., Blejan, H., Poenaru, M., and Costache, R.S. (2023). Skin Cancer Correlations in Psoriatic Patients. Cancers, 15.","DOI":"10.3390\/cancers15092451"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/PTT.S342911","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies","volume":"11","author":"Balak","year":"2021","journal-title":"Psoriasis Targets Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: Classical and emerging comorbidities","volume":"90","author":"Duarte","year":"2015","journal-title":"An. Bras. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5114\/ada.2019.83983","article-title":"Non-alcoholic fatty liver disease in patients with psoriasis: Therapeutic implications","volume":"37","author":"Klujszo","year":"2020","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s10067-019-04646-7","article-title":"Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients","volume":"38","author":"Ortolan","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Olveira, A., Augustin, S., Benlloch, S., Ampuero, J., Su\u00e1rez-P\u00e9rez, J.A., Armesto, S., Vilarrasa, E., Belinch\u00f3n-Romero, I., Herranz, P., and Crespo, J. (2023). The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life, 13.","DOI":"10.3390\/life13020419"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts","volume":"24","author":"Papatheodoridi","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13244-016-0514-5","article-title":"ARFI: From basic principles to clinical applications in diffuse chronic disease\u2014A review","volume":"7","author":"Bruno","year":"2016","journal-title":"Insights Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison","year":"2019","journal-title":"Postgrad. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jhep.2010.11.021","article-title":"Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease","volume":"55","author":"Tandra","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.16239","article-title":"Nonalcoholic fatty liver disease in patients with psoriasis: A consequence of systemic inflammatory burden?","volume":"179","author":"Prussick","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5114\/amsad.2018.81184","article-title":"Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study","volume":"3","author":"Szczepanek","year":"2018","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Piazzolla, V.A., and Mangia, A. (2020). Noninvasive diagnosis of NAFLD and NASH. Cells, 9.","DOI":"10.3390\/cells9041005"},{"key":"ref_23","first-page":"517","article-title":"Non-alcoholic fatty liver disease and psoriasis\u2014Is there a shared proinflammatory network?","volume":"19","author":"Heitmann","year":"2021","journal-title":"JDDG J. Ger. Soc. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in NAFLD\u2014Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI96139","article-title":"Insulin resistance causes inflammation in adipose tissue","volume":"128","author":"Shimobayashi","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Duvnjak","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study","volume":"70","author":"Koehler","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.3748\/wjg.15.6023","article-title":"Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression","volume":"15","author":"Duvnjak","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Calton, E.K., Keane, K.N., Newsholme, P., and Soares, M.J. (2015). The impact of Vitamin D levels on inflammatory status: A systematic review of immune cell studies. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141770"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ajpath.2016.05.012","article-title":"High-Fat Diet\u2013Induced IL-17A Exacerbates Psoriasiform Dermatitis in a Mouse Model of Steatohepatitis","volume":"186","author":"Vasseur","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Visser, M.J.E., Kell, D.B., and Pretorius, E. (2019). Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00007"},{"key":"ref_39","first-page":"66","article-title":"Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD)","volume":"59","author":"Darmadi","year":"2021","journal-title":"Rom. J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Gisondi, P., Lonardo, A., and Targher, G. (2016). Relationship between non-alcoholic fatty liver disease and psoriasis: A novel Hepato-Dermal axis?. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020217"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1150.e1","DOI":"10.1016\/j.amjmed.2009.06.021","article-title":"Comorbidities in Patients with Psoriasis","volume":"122","author":"Gottlieb","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0378-6323.115506","article-title":"Comorbidities in psoriasis","volume":"79","author":"Aurangabadkar","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: What is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2015.00001","article-title":"Management of moderate to severe psoriasis in patients with metabolic comorbidities","volume":"2","author":"Gisondi","year":"2015","journal-title":"Front. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1096\/fj.07-100685","article-title":"Ecto-5\u2032-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis","volume":"22","author":"Peng","year":"2008","journal-title":"FASEB J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjms.2017.03.014","article-title":"Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease","volume":"354","author":"Shetty","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e14281","DOI":"10.1111\/dth.14281","article-title":"Methotrexate vs. secukinumab safety in psoriasis patients with metabolic syndrome","volume":"33","author":"Gisondi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2020.1703948","article-title":"Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Ure","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","article-title":"The pharmacological management of patients with comorbid psoriasis and obesity","volume":"20","author":"Chiricozzi","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tox.2013.01.020","article-title":"Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: Potential mechanisms of hepatotoxicity","volume":"306","author":"Silva","year":"2013","journal-title":"Toxicology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ajd.13175","article-title":"Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate\u2013severe psoriasis: A cross-sectional cohort study","volume":"61","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000351769","article-title":"The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: A noncontrolled study","volume":"227","author":"Karadag","year":"2013","journal-title":"Dermatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jdv.13456","article-title":"Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis","volume":"30","author":"Gisondi","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_59","first-page":"39","article-title":"Biologic treatments of psoriasis: An update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_60","first-page":"e1","article-title":"Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014Update 2015\u2014EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ad.2016.12.017","article-title":"Psoriasis and Nonalcoholic Fatty Liver Disease","volume":"108","author":"Carrascosa","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-\u03b1 antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.17235\/reed.2019.6263\/2019","article-title":"Psoriasis and fatty liver: A harmful synergy","volume":"111","author":"Olveira","year":"2019","journal-title":"Rev. Esp. Enfermedades Dig."},{"key":"ref_65","first-page":"43","article-title":"Nonalcoholic Fatty Liver Disease and Psoriasis What a Dermatologist Needs to Know","volume":"8","author":"Prussick","year":"2015","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/kex186","article-title":"The role of IL-12\/23 in T cell-related chronic inflammation: Implications of immunodeficiency and therapeutic blockade","volume":"57","author":"Schurich","year":"2018","journal-title":"Rheumatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ad.2015.02.002","article-title":"An\u00e1lisis de la hepatotoxicidad en psoriasis tratada con ustekinumab. Estudio retrospectivo de 44 pacientes en pr\u00e1ctica cl\u00ednica habitual","volume":"106","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00403-014-1495-1","article-title":"Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: A retrospective cohort study of 111 patients","volume":"306","author":"Yanaba","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20406223211046685","DOI":"10.1177\/20406223211046685","article-title":"Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: A real-world practice","volume":"12","author":"Hung","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Xu, X., Su, L., Gao, Y., and Ding, Y. (2017). The prevalence of nonalcoholic fatty liver disease and related metabolic comorbidities was associated with age at onset of moderate to severe plaque psoriasis: A cross-sectional study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169952"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1111\/ajd.13015","article-title":"Relationship between psoriasis and non-alcoholic fatty liver disease\u2014Updated systematic review and adjusted meta-analysis","volume":"60","author":"Phan","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_76","first-page":"263","article-title":"Relationship between psoriasis and non-alcoholic fatty liver disease","volume":"11","author":"Narayanasamy","year":"2016","journal-title":"Prz. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/apt.13042","article-title":"The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic","volume":"41","author":"Roberts","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: An updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PTT.S272286","article-title":"Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter","volume":"10","author":"Gandha","year":"2020","journal-title":"Psoriasis Targets Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1478-3231.2012.02820.x","article-title":"Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography","volume":"32","author":"Vergniol","year":"2012","journal-title":"Liver Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.47162\/RJME.61.2.20","article-title":"The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients","volume":"61","author":"Neagoe","year":"2020","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Le, M.H., Devaki, P., Ha, N.B., Jun, D.W., Te, H.S., Cheung, R.C., and Nguyen, M.H. (2017). Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173499"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"907729","DOI":"10.3389\/fimmu.2022.907729","article-title":"Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_86","first-page":"e304","article-title":"Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk","volume":"60","author":"Bellot","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/ajd.12460","article-title":"Psoriasis and the liver: Problems, causes and course","volume":"58","author":"Tula","year":"2017","journal-title":"Australas. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/09546634.2021.1922572","article-title":"The risk of hepatic adverse events of systemic medications for psoriasis: A prospective cohort study using the BIOBADADERM registry","volume":"33","author":"Rivera","year":"2022","journal-title":"J. Dermatol. Treat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2660\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:29Z","timestamp":1760105069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052660"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052660","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]}}}